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Therapy of acute myeloid leukemia in older persons is associatedwith poor outcomes because of intolerance to intensive therapy,resistant disease and co-morbidities. This multi-center, random-
ized, open-label, phase II trial compared safety and efficacy of three ther-
apeutic strategies in patients 65 years or over with newly-diagnosed
acute myeloid leukemia: 1) continuous high-dose lenalidomide (n=15);
2) sequential azacitidine and lenalidomide (n=39); and 3) azacitidine
only (n=34). The efficacy end point was 1-year survival.  Median age
was 76 years (range 66-87 years). Thirteen subjects (15%) had prior
myelodysplastic syndrome and 41 (47%) had  adverse cytogenetics.
One-year survival was 21% [95% confidence interval (CI): 0, 43%] with
high-dose lenalidomide, 44% (95%CI: 28, 60%) with sequential azaciti-
dine and lenalidomide, and 52% (95%CI: 35, 70%) with azacitidine
only.  Lenalidomide at a continuous high-dose schedule was poorly-tol-
erated resulting in a high rate of early therapy discontinuations. Hazard
of death in the first four months was greatest in subjects receiving con-
tinuous high-dose lenalidomide; hazards of death thereafter were simi-
lar. These data do not favor use of continuous high-dose lenalidomide or
sequential azacitidine and lenalidomide over the conventional dose and
schedule of azacitidine only in patients aged 65 years or over with
newly-diagnosed acute myeloid leukemia. (clinicaltrials.gov identifier:
01358734).
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ABSTRACT
Introduction
The incidence of acute myeloid leukemia (AML) increases dramatically with
age.  Survival of older people with AML is poor;1-3   in the US, fewer than 50% of
subjects with AML over 65 years of age receive therapy within three months of
diagnosis despite considerable data indicating therapy improves their survival.4-6
Reasons for not treating older patients with AML include poor performance score,
co-morbidities, frailty, an antecedent hematologic disorder (AHD), presumed ther-
apy-related leukemia, and/or adverse risk biological features.4,7  One study of more
than 3000 subjects reported a significant adverse impact of increasing age on out-
comes even after adjusting for these variables, suggesting age is an independent
prognostic variable associated with poor outcomes.8
Therapy recommendations for older subjects with AML vary with no standard-
of-care.7 Commonly-used treatments include intensive therapy (typically cytara-
bine and an anthracycline) and less intensive approaches such as low-dose cytara-
bine or DNA hypo-methylating drugs including azacitidine and decitabine.9
Azacitidine was recently approved in Europe in subjects
65 years and over with AML and more than 30% bone
marrow blasts judged unfit for a hematopoietic cell trans-
plant.8 Approval was based on a 4-month improvement in
median survival compared with conventional therapy or
supportive care [10.4 vs. 6.5 months; Hazard Ratio (HR)
0.85, 95% confidence interval (95%CI): 0.69, 1.03].
Considerable data indicate high-dose lenalidomide, an
immune-modulatory drug (IMiD®), may be effective in
patients with myelodysplastic syndrome (MDS) with
excess blasts and patients with AML judged unfit for
intensive therapy.10,11 Phase I and II studies report con-
comitant or sequential azacitidine and lenalidomide is
effective in MDS, AML and in chronic myelomonocytic
leukemia (CMML).12-15  
Several studies of lenalidomide used 50 mg/day contin-
uously without dose modification. Based on these data,
we designed a randomized phase II study comparing safe-
ty and efficacy of continuous high-dose lenalidomide,
sequential azacitidine and lenalidomide or azacitidine
only in persons 65 years or over with newly-diagnosed
AML. 
Methods
We conducted a phase II randomized, open-label, parallel-group
study at 25 sites in North America (clinicaltrials.gov identifier:
01358734). The study was approved by the relevant institutional
review boards or an independent ethics committee, and followed
guidelines  set out in the Declaration of Helsinki. Subjects gave
written informed consent.  Statistical analyses were carried out by
Celgene Corporation, Summit, NJ, USA, and were reviewed by
the authors with access to all study data.  
Subjects
Eligible subjects were 65 years and over with newly-diagnosed
AML including those with de novo AML, AML with prior MDS or
with presumed therapy-related AML. Subjects could not have pre-
viously received lenalidomide, azacitidine, decitabine or cytara-
bine and were judged ineligible to receive a transplant at 
study entry. Subjects had to have an Eastern Co-operative
Oncology Group (ECOG) performance score ≤2, white blood cell
(WBC) count ≤10x109/L (hydroxyurea use was permitted to lower
the WBC count), adequate liver and kidney function, and no
uncontrolled infection or other cancer within two years of study
entry. Subjects who had received prior therapy for AML other
than hydroxyurea were not eligible for the study.
Study design
Screening procedures were completed no more than 28 days
before randomization. Confirmation of AML for study entry was
based on local pathology review. A separate central review of all
bone marrow aspirates, bone marrow biopsies and blood smears
was conducted by a blinded pathologist (Dr. Daniel Arber,
Stanford University). Cytogenetic testing on diagnostic samples
was carried out locally and reviewed centrally (Prof. Athena
Cherry, Stanford University). Subjects were randomized equally
to the therapy arms by central interactive voice response system
(IVRS). Randomization was stratified for performance score (0-1
vs. 2) and levels of blood myeloblasts (<1 vs. ≥1x109/L).
Therapy
Therapy regimens are shown in Figure 1. Therapy in any arm
could be interrupted or delayed because of hematologic or non-
hematologic therapy-related adverse events (AEs).  Lenalidomide
dose-reductions were not allowed in cycles 1-4 in the continuous
high-dose lenalidomide cohort or in courses 1 and 2 in the azaci-
tidine and lenalidomide cohort. Dose reductions of lenalidomide
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Figure 1.  Study design and ther-
apy regimens. Stratification fac-
tors were Eastern Co-operative
Oncology Group (ECOG) perform-
ance score (0-1 vs. 2) and blood
blast level (<1 vs. ≥1x109/L).
Randomization in the lenalido-
mide regime was suspended 11th
September 2013 and permanent-
ly closed on 15th April 2014 as per
Amendment 2 because of the
high rate of discontinuation of the
study treatment in subjects
receiving high-dose continuous
lenalidomide. AML: acute myeloid
leukemia; PO: per oral administra-
tion; SC: subcutaneous injection;
SPM: secondary primary malig-
nancies.
could be made thereafter in both cohorts.  Dose reductions of
azacitidine were permitted as described. Dose reductions of
lenalidomide or azacitidine were continued in subsequent cycles
unless additional adverse events occurred; in such cases, additional
dose reductions were permitted. Subjects were seen weekly for
the first 2 courses, every two weeks for the next 2 courses, and on
the first day of subsequent courses. Microscope slides of blood
and bone marrow samples and cytogenetic testing were obtained
pre-randomization, on day 15 of course 1, within seven days of
beginning  courses 2 and 3, and before starting every third  subse-
quent course.
Safety and efficacy end points
Safety assessments included vital signs, physical exam, weight,
ECOG performance score, complete blood count (CBC) and dif-
ferential, blood chemistries, urinalyses, coagulation, thyroid func-
tion tests and electrocardiograms.  AEs were recorded using
Common Terminology Criteria for Adverse Events (CTCAE)
v.4.0. Study subjects were kept under surveillance for the develop-
ment of new cancers.  Events of interest (EOIs) were recorded and
reported as serious AEs (SAEs) and considered medically-impor-
tant even if not meeting SAE criteria. The primary end point was
1-year survival.  Secondary end points included rates of complete
remission (CR), complete remission with incomplete recovery of
neutrophils or platelets (CRi), and remission duration.  Subjects
discontinuing the study could receive subsequent therapy during
the follow-up interval at their physician’s discretion and with their
consent.
Statistical analysis
The study was not designed or powered for a formal statistical
comparison of the therapy cohorts and a sample size calculation
was not made. Target enrollment was 40 subjects per cohort.
Preliminary analyses indicated a high rate of discontinuations in
the continuous high-dose lenalidomide cohort with 10 of the first
13 subjects receiving less than 56 days of therapy.  Based on these
data, the Data Safety Monitoring Committee (DSMC) recom-
mended closing randomization into this cohort and the planned
study sample size was reduced to 95 subjects.
Time-to-death from any cause was defined as the interval from
randomization to death.  Living subjects were censored at date of
last contact, withdrawal of consent, loss to follow up, or study
completion.  There was no pre-specified statistical plan to com-
pare survival between the cohorts. However, an exploratory
analysis was made comparing 1-year survival Kaplan-Meier esti-
mates between the cohorts using the log rank test and which indi-
cated non-proportional hazards of death.  Consequently, we esti-
mated HR and 95% confidence intervals for the intervals 0-4
months and >4-12 months using a Cox proportional hazards
model. P-values were derived from the Cox model.
Results
Subjects
Enrollment began on 27th April 2012 with database lock
on 1st May 2015.  Because of poor accrual, only 88 subjects
were randomized, all of whom constitute the intent-to-
treat (ITT) population including 15 subjects randomized to
receive high-dose continuous lenalidomide, 39 random-
ized to receive sequential azacitidine and lenalidomide,
and 34 randomized to receive azacitidine only.  Subjects in
the high-dose lenalidomide cohort were more likely to be
over 75 years of age and to have had prior MDS, had a
higher percent of bone marrow blasts, and  lower levels of
blood neutrophils. This cohort also had fewer subjects
with adverse cytogenetics than the other cohorts (Table
1).  There were 6 subjects with del(5/5q), including one
each in the high-dose lenalidomide and in the azacitidine
only cohorts, and 4 in the sequential azacitidine and
lenalidomide cohort.
Efficacy
Median therapy duration was six weeks (range 1-48
weeks) for the continuous high-dose lenalidomide cohort,
eight weeks (0-78 weeks) for the sequential azacitidine
and lenalidomide cohort, and 29 weeks (1-143 weeks) for
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Table 1. Baseline variables for the intent-to-treat populations.
                                               Lenalidomide Azacitidine+     Azacitidine
                                                    (n=15) lenalidomide       (n=34)
                                                          (n=39)
Age (years)                                                                           
Median (range)                                80 (68-85) 76 (66-87)         75 (66-85)
>75 years (n)                                           10 21                        14
Male (n)                                                    12 22                        19
ECOG performance score (n)                                         
0-1                                                               13 32                        27
2                                                                   2 7                          6
Prior MDS (n)                                           3 5                          5
Adverse cytogenetics (n)                       4 20                        17
Blood blasts >1x10E9/L (n)                  11 31                        27
Bone marrow blasts (%)                                                   
Median (range)                                56 (22-95) 37 (12-84)         34 (14-70)
Interval from diagnosis 
to treatment  (days)                                                         
Median (range)                                 15 (7-42) 18 (4-41)           16 (6-50)
Platelets (x109/L)                                                                 
Median (range)                                54 (8-162) 72 (13-204)        56 (8-211)
Neutrophils (x109/L)                                                           
Median (range)                                0.2 (0-1.6) 0.4 (0-3)            0.5 (0-3) 
n: number; ECOG: Eastern Co-operative Oncology Group; MDS: myelodysplastic syn-
dromes; d: days.
Table 2. Hazard Ratios for death.
                                                     Hazard Ratio (95% CI)            P
0-4 months                                                                                                       
Lenalidomide vs. azacitidine                 5.73 (1.90, 17.20)                 0.002
Azacitidine + lenalidomide vs.              2.51 (0.89, 7.05)                  0.081
azacitidine                                                                 
Lenalidomide vs.                                      2.19 (0.94, 5.13)                  0.071
azacitidine + lenalidomide                                   
>4-12 months                                                                                                  
Lenalidomide vs. azacitidine                0.853 (0.187, 3.90)                0.838
Azacitidine + lenalidomide vs.            0.790 (0.312, 2.00)                0.620
azacitidine                                                                 
Lenalidomide vs. azacitidine +             1.02 (0.22, 4.80)                  0.982
lenalidomide                                                            
CI: Confidence Interval; P: P-value; vs.: versus.
the azacitidine only cohort. The most common reason for
discontinuation was leukemia progression in 5, 11, and 13
subjects (Figure 2). 
One-year survivals were 21% (95%CI: 0, 43%), 44%
(95%CI: 28, 60%) and 52% (95%CI: 35, 70%) (Figure 3)
in the lenalidomide, azacitidine and lenalidomide and
azacitidine only cohorts.  Subjects in the high-dose contin-
uous lenalidomide cohort had a higher hazard of death
than subjects in the azacitidine cohort [HR 5.73 (1.91,
17.20); P=0.002] or subjects in the sequential azacitidine
and lenalidomide cohort [HR 2.19 (95%CI: 0.94, 5.13);
P=0.071] (Table 2) in the first four  months post random-
ization. Hazard of death was also higher in the sequential
azacitidine and lenalidomide cohort compared with the
azacitidine cohort [HR 2.51 (0.89, 7.05); P=0.081].
Hazards of death >4-12 months were similar in the 3
cohorts.
There were 7 deaths in the continuous high-dose
lenalidomide cohort in the first four  months.  Median
duration of therapy of these subjects was 36 days (range
7-84 days). Two subjects discontinued therapy because of
an adverse event and 5 because of AML progression.
Causes of death were AML and/or its complications such
as infection. One subject had a pulmonary infarct.  Rates
of CR and CRi for the cohorts are shown in Table 3.
Interestingly, 2 subjects receiving high-dose lenalidomide
only, a non-cytotoxic drug, achieved a complete remission
and 3, a complete remission with incomplete recovery of
blood levels of neutrophils and/or platelets. There were
too few subjects with del(5/5q) in each cohort to compare
outcomes of this subset.
Adverse events
Eighty-four subjects received 1 dose or more of study
drug and constitute the safety population including 14
subjects receiving high-dose continuous lenalidomide, 38
receiving sequential azacitidine and lenalidomide, and 32
receiving azacitidine only.  Treatment was discontinued
within the first 2 cycles in 10 subjects in the high-dose
continuous lenalidomide, 19 in the sequential azacitidine
and lenalidomide cohort, and 8 in the azacitidine only
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Figure 2. CONSORT study-flow diagram. *Four randomized subjects were not treated because of withdrawal of consent, adverse events, or other reasons, e.g.  hos-
pitalization. Percents are based on the intention-to-treat population.
Table 3. Proportion of subjects with complete remission with (CR) and
without (CRi) complete hematologic recovery.
CR CRi CR/CRi
Lenalidomide (n=15) 2 3 5
Azacitidine + lenalidomide (n=39) 11 4 15
Azacitidine (n=34) 6 8 14
n: number.
cohort.  The most common reasons for discontinuation of
study therapy within 2 courses across the 3 cohorts were
adverse events (3, 6 and 2, respectively), death (2, 6 and 1,
respectively) and disease progression (3, 2 and 2, respec-
tively).  During the study the proportion of treatment-
emergent adverse events (TEAEs) resulting in therapy dis-
continuation was highest in the high-dose continuous
lenalidomide cohort (n=4) followed by the azacitidine and
lenalidomide cohort (n=7), and lowest in the azacitidine
only cohort (n=3).  Infections were the most frequent
cause of permanent therapy discontinuation and were
most frequent in the high-dose continuous lenalidomide
cohort (n=4 compared with 3 subjects in the azacitidine
and lenalidomide cohort and 1 subject in the azacitidine
only cohort). There were 3 new cancers (vulvar cancer,
stage 0; lung adenocarcinoma; and central nervous system
cancer), all in the azacitidine only cohort. These cancers
were diagnosed at approximately, 6, 9 and less than 1
month post randomization.
The most frequent TEAEs (any grade) considered drug-
related were hematologic and gastrointestinal.  The most
frequent TEAE  grade 3 or over was febrile neutropenia
(n=6, 17 and 9, respectively) (Table 4).  Frequencies of
treatment-emergent serious AEs (TE-SAEs) was higher in
the high-dose continuous lenalidomide cohort (n=10) than
in the other cohorts (n=16 and 7, respectively).
Pneumonia was the most frequent infectious TE-SAE
reported in 1, 2 and 0 subjects, respectively.  The most
common causes of death on therapy were AML progres-
sion and infections. Deaths from AML progression were
reported in 8, 12 and 11 subjects and deaths from infec-
tions were reported in 2, 5 and 2 subjects, respectively.
Median hospital days for the 3 cohorts were ten days
(range 2-54 days), 11 days (range 2-43 days), and seven
days (range 2-24 days).
Discussion
Our randomized phase II study in patients over 65 years
with newly-diagnosed AML was designed to numerically
compare 1-year survivals between the cohorts.  It was not
designed nor powered to make statistical comparisons in
outcomes. The sequential azacitidine and lenalidomide
and azacitidine only regimens were reasonably well-toler-
ated. Proportions of subjects alive at one year in these
cohorts were 52% (35, 70%) and 44% (28, 60%), similar
to azacitidine only in a large phase III trial in similar
patients.16 However, the HR for death of 2.51 (0.89, 7.05)
in the lenalidomide plus azacitidine cohort in months 0-4
suggests azacitidine only may be the best regimen.
Lenalidomide at the dose and schedule used in the high-
dose continuous lenalidomide cohort was less well-toler-
ated, perhaps because no dose reduction was permitted,
resulting in a high proportion of early treatment discontin-
uation and in subsequent leukemia progression.  Subjects
High-dose LEN and AZA in newly-diagnosed AML
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Table 4. Most common (≥3 subjects) grade ≥3 treatment-emergent
adverse events.
Preferred term Lenalidomide Azacitidine + Azacitidine
(n=14) lenalidomide (n=32)
(n=38)
≥1 CTCAE ≥grade-3 TEAE 14 34 29
Febrile neutropenia 6 17 9
Thrombocytopenia 4 12 11
Anemia 4 10 8
Neutropenia 3 5 9
Pneumonia 3 2 8
Cellulitis 0 5 4
Neutrophil count decreased 0 5 4
WBC decreased 0 4 5
Platelet count decreased 0 6 2
Dyspnea 2 4 1
Fatigue 4 6 5
Syncope 3 1 3
Atrial fibrillation 0 4 0
CTCAE: Common Terminology Criteria for Adverse Events; TEAE: treatment-emergent
adverse event; WBC: white blood cell count. Subjects with multiple occurrences of the
same TEAE were counted only once and assigned the highest grade reported. Data
cut-off date: 1st May 2015.  Preferred terms are according to MedDRA dictionary, v. 17.0
and listed in descending order of overall frequency.  
Figure 3. Kaplan-Meier estimates of 1-
year survival. Subjects in the high-dose
continuous lenalidomide cohort had a
higher hazard of death in 0-4 months than
subjects in the azacitidine alone cohort
(P=0.002) and subjects in the sequential
azacitidine and lenalidomide cohort
(P=0.071).
enrolled in this cohort had an increased hazard of death in
the  first four months of therapy compared with the other
cohorts.  Hazards of death thereafter were similar but
favor the azacitidine cohort.  This early difference in haz-
ard of death should be viewed cautiously as these analy-
ses were not specified in the pre-study statistical plan and
sample sizes are small.  Proportions of subjects achieving
a CR/CRi were similar with wide 95% confidence inter-
vals. It is also important to emphasize that the small sam-
ple sizes may have resulted in an imbalance in baseline
variables. For example, subjects in the high-dose continu-
ous lenalidomide cohort were older and more likely to
have prior MDS and severe bone marrow failure but less
frequent adverse cytogenetics. This cohort also had a
greater proportion of subjects with cardio-vascular disease
risk factors (data not shown).  None of these differences
were tested for statistical significance according to the pre-
study statistical plan.  Finally, discontinuation rates were
generally similar to those in other clinical studies of con-
tinuous high-dose lenalidomide in older persons with
AML.14 Randomization with or without stratification does
not guarantee cohorts have similar distributions of known
and latent prognostic variables, especially when there are
few subjects in each cohort. Typically, potential imbal-
ances are accounted for by calculating P-values and indi-
cating confidence intervals. Because we did not perform
these calculations for outcomes other than for 0-4 and >4-
12-month survival intervals between the cohorts, differ-
ences in outcomes should not be assumed to result from
therapy assignment.
Sequential azacitidine and lenalidomide did not increase
the frequency of >grade 3 or over TEAEs compared with
continuous high-dose lenalidomide. Subjects in the con-
tinuous high-dose lenalidomide cohort were scheduled to
receive 50 mg/day for 56 days whereas those in the
sequential azacitidine and lenalidomide cohort were
scheduled to receive the same dose of lenalidomide for 21
days followed by 14 days off therapy. Consequently, there
are significant differences in schedule and total dose of
lenalidomide between the cohorts. Neither regimen with
high-dose lenalidomide, continuous or sequential, was as
well-tolerated as azacitidine only.
In conclusion, data from unplanned survival analysis
indicate high-dose continuous lenalidomide given without
dose reduction resulted in a high rate of early discontinu-
ations and an early but not late increased hazard of death
compared with sequential azacitidine and lenalidomide
and with azacitidine only in subjects 65 years and over
with newly-diagnosed AML. Our data also suggest thera-
py with azacitidine only may be better than sequential
lenalidomide and azacitidine based on the 95% confi-
dence interval of the HR for death. Although continuous
high-dose lenalidomide is active in AML and sometimes
produces prolonged complete remissions,10 we cannot rec-
ommend the dose and schedule we tested for subjects 65
years and over with newly-diagnosed AML. Adding
lenalidomide to azacitidine did not improve 1-year sur-
vival and may have reduced it in the first four months of
therapy. However, our study was neither designed nor
powered to test this question. Whether a different dose,
schedule and/or dose-modification of lenalidomide alone
or with azacitidine might be better tolerated and/or more
effective than the dose and schedule we studied is
unknown. However, the achievement of complete remis-
sion with or without complete recovery of blood levels of
neutrophils and/or platelets by a non-cytotoxic drug is
noteworthy.
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